Study to evaluate the safety and efficacy of Avacopan in subjects with moderate to severe hidraentis suppurativa
You are being invited to participate in a research study because you have hidradenitis suppurativa (HS), also called acne inversa. Avacopan is an investigational drug being studied to learn if it is safe and effective for the treatment for HS.
Currently, the treatment for patients with HS includes local and systemic antibiotics, pain medication, and anti-TNF-a agents such as adalimumab. Acitretin is used in early stage disease. Other drugs such as cyclosporin, dapsone, and isotretinoin have been used with limited success. In HS disease, neutrophils, which are a type of white blood cells of the immune system, are attracted to the HS lesions. C5a is a protein of the immune system which is also located in the skin. C5a attracts neutrophils and binds to the C5a receptor (C5aR) of the neutrophils hereby contributing to the inflammation of the HS lesions. Avacopan binds and blocks the C5a receptor (or C5aR) of the neutrophils; this blockage means that the receptor can no longer be activated by C5a and the movement and binding of neutrophils to the site of inflammation through C5a is interrupted.
- Study Identifier: 833016
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required